SCHEMBL20746152

SCHEMBL20746152

O=C(O)NC[C@@H](c1ccccc1)N1CCOCC1

nearest known ligand 0.60

Predicted protein targets (top 14)

geneUniProtsupporting neighboursconfidence
P2RX7 Q99572 8/20 0.60
THRB P10828 1/20 0.59
CYP3A4 P08684 1/20 0.59
CYP2C9 P11712 1/20 0.59
CYP2C19 P33261 1/20 0.59
ALDH1A1 P00352 4/20 0.58
MAPT P10636 3/20 0.58
RAB9A P51151 1/20 0.58
SMN1; SMN2 Q16637 1/20 0.58
LMNA P02545 1/20 0.57
KDM4E B2RXH2 1/20 0.56
HSD17B10 Q99714 1/20 0.56
TP53 P04637 1/20 0.56
MAPK1 P28482 1/20 0.55

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL5067765 0.83 TP53 (0.57) P2RX7THRBALDH1A1MAPTLMNA
SCHEMBL7695920 0.81 ALDH1A1 (0.51) P2RX7CYP3A4CYP2C9CYP2C19ALDH1A1
SCHEMBL28276335 0.81 ALDH1A1 (0.51) THRBCYP3A4CYP2C9CYP2C19ALDH1A1
SCHEMBL8276876 0.80 ALDH1A1 (0.49) P2RX7THRBCYP3A4CYP2C9CYP2C19
SCHEMBL1243390 0.80 ALDH1A1 (0.51) P2RX7THRBCYP3A4CYP2C9CYP2C19
SCHEMBL6318911 0.79 CYP2C19 (0.74) CYP3A4CYP2C9CYP2C19ALDH1A1MAPT
SCHEMBL16463886 0.79 P2RX7 (0.67) P2RX7THRBCYP3A4CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL20600115 0.79 LMNA (0.51) P2RX7THRBCYP3A4CYP2C9CYP2C19
Hydrochloric Acid SCHEMBL21838887 0.79 LMNA (0.51) P2RX7THRBCYP3A4CYP2C9CYP2C19
SCHEMBL11651599 0.78 OPRL1 (0.58) CYP3A4CYP2C19ALDH1A1HSD17B10

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
WO-2019036024-A1 2-(1,1 '-BIPHENYL)-1 H-BENZO[D]IMIDAZOLE DERIVATIVES AND RELATED COMPOUNDS AS APELIN AND APJ AGONISTS FOR TREATING CARDIOVASCULAR DISEASES BRISTOL-MYERS SQUIBB COMPANY (US) 2019-02-21 WO disclosed